KNEE SURGERIES AND ARTHROPLASTY PAIN MANAGEMENT THERAPEUTICS MARKET ANALYSIS

Surge in the number of knee surgeries and arthroplasty and rising awareness about knee surgeries and arthroplasty is expected to drive growth of the knee surgeries and arthroplasty pain management therapeutics market during the forecast period

For instance, in October 2018, Apollo Hospitals, Aragonda conducted a Walkathon event with the main objective of promoting walking for pain free knees. The purpose of the event was to raise awareness about arthritis and how to overcome it with the World Arthritis Day theme. The Apollo Hospitals introduced Total Knee Replacement (TKR) surgeries at its Aragonda unit and since then, as many as 65 surgeries had been done at an affordable cost. Apollo Hospitals, Aragonda created awareness among people about the importance of total knee replacement (TKR) surgeries.  

The global knee surgeries and arthroplasty pain management therapeutics market is estimated to be valued at US$ 4,211.7 million in 2022 and expected to exhibit a CAGR of 4.8% over the forecast period (2022-2030).

Figure 1. Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market Share (%) in Terms of Value, By Region, 2022

To learn more about this report, request a free sample copy

Key players operating in the market are focusing on the development and approval of novel therapeutics for the treatment of knee surgeries and arthroplasty pain, which is expected to offer a lucrative opportunity for market players to launch innovative products in the market

For instance, in December 2021, Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that the U.S. Food and Drug Administration (FDA) had approved its supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to significantly expand the indication. ZYNRELEF is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Figure 2. Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market Share (%), by Distribution Channel, 2022

To learn more about this report, request a free sample copy

Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market: Restraint

The growth of the global knee surgeries and arthroplasty pain management therapeutics market may be hampered, owing to product recalls and side effects associated with the use of medication

For instance, in April 2021, A-S Medication Solutions, LLC (ASM), formerly Allscripts Medication Services Group (founded in 1988) – the industry leader in providing complete, end-to-end turnkey, on-site medication dispensing solutions, voluntarily recalled 198,350 bottles of Acetaminophen Extra Strength 500 mg Tablets, 100 ct. bottles contained in Health Essentials Kits distributed by Humana, a for-profit American health insurance company, to its members. This recall was conducted to the consumer level. These over-the-counter (OTC) analgesic products contain an incomplete prescription drug label rather than the required over-the-counter (OTC) drug facts label.

Moreover, some common side effects of COX-2 inhibitors include abdominal pain, headache, nausea, diarrhea, flatulence, and insomnia. COX-2 inhibitors and other Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of heart attacks, stroke, and related conditions, which can be fatal. This risk may increase with the duration of use in patients who have underlying risk factors for disease of the heart and blood vessels.

Key Players

Major players operating in the global knee surgeries and arthroplasty pain management therapeutics market include Pfizer Inc, Allay Therapeutics, Mallinckrodt, Johnson & Johnson, Zydus Cadila Healthcare Ltd., Novartis AG, Purdue Pharma, Delphis Pharmaceutical, Taj Pharmaceuticals Limited, GlaxoSmithKline plc, AbbVie Inc., and Aurobindo Pharma